Key Insights:
- A phase 2 placebo-controlled trial found that six months of daily low-dose aspirin reduced liver fat content in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) without cirrhosis.
- Aspirin use improved several markers of liver health associated with inflammation and fibrosis.
- Conducted by Massachusetts General Hospital, the study involved 80 participants with MASLD. The aspirin-treated group showed a 6.6% reduction in liver fat content compared to a 3.6% increase in the placebo group.
- Aspirin treatment led to a significant reduction in liver fat content and was well-tolerated by participants, with similar adverse event rates in both the aspirin and placebo groups.
- Aspirin may offer a low-cost option to prevent progression to cirrhosis or liver cancer in MASLD patients.